In 2012, Fiji introduced rotavirus vaccine (Rotarix, GSK) into the national 
immunisation schedule. We describe the intussusception epidemiology prior to 
rotavirus vaccine, temporal association of intussusception cases to 
administration of rotavirus vaccine, and estimate the additional number of 
intussusception cases that may be associated with rotavirus vaccine. A 
retrospective review of intussusception cases for children aged <24 months old 
was undertaken between January 2007 and October 2012 pre-vaccine. All admissions 
and deaths with a discharge diagnosis of intussusception, bowel obstruction, 
paralytic ileus, or intussusception ICD10-AM codes were extracted from national 
databases and hospital records. Nationwide active intussusception surveillance 
was established for three years post-vaccine (2013-2015). There were 24 definite 
intussusception cases in the pre-rotavirus vaccine period, 96% were confirmed by 
surgery. The median age was 6.5 months. The incidence rate was 22.2 (95% CI: 
13.9-33.7) per 100,000 infants. There were no deaths. Active surveillance 
identified 25 definite intussusception cases, 96% of which were among children 
who were age-eligible for rotavirus vaccine. None were potentially vaccine 
related. We estimated one to five additional  cases of intussusception every 
five years. The incidence of intussusception pre-rotavirus vaccine in Fiji is 
low. Intussusception associated with rotavirus vaccine is likely a rare event in 
Fiji.